Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that administering finasteride reduced levels of certain neuroactive androgens in rat brains, suggesting peripheral origin for most 3α,5α-Adiol and brain synthesis for 3α,5α-A.

This study found that subchronic finasteride treatment in male rats altered neuroactive steroid levels and steroid receptor expression in the brain, with some changes persisting after drug withdrawal.

This review discusses the potential persistent adverse effects associated with 5α reductase inhibitor treatment for androgenetic alopecia but provides no new clinical results; it emphasizes the importance of discussing these risks with patients.

In this study, adolescents with depressive symptoms were found to have higher urinary excretion rates of certain steroid metabolites, including corticosterone and adrenal hormones, and a specific metabolite ratio was identified as a potential biomarker for distinguishing these patients from healthy controls.

This study found that low-dose finasteride treatment in men with premature androgenetic alopecia decreased levels of 5α-reduced steroids, which may be linked to increased depression symptoms.

This review discusses the effects of neuroactive testosterone metabolites on CNS functions and suggests their potential as therapeutic options for neurological disorders, but reports no new clinical results.

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This review highlights the need for a deeper understanding of 5alpha-reductases and neuroactive steroids to reduce potential adverse effects of 5alpha-reductase inhibitors used for conditions like benign prostatic hyperplasia and androgenic alopecia, but reports no new clinical results.

This review outlines the physiological roles of 5a-reductases and highlights the need for further research to better understand their function and minimize adverse effects from their inhibitors used in treatment.

This study on male rats found that finasteride treatment led to the differential expression of several genes in the hypothalamus and hippocampus, hinting at potential links to observed side effects like depression, anxiety, and cognitive disturbances.

This study reports that men with androgenic alopecia experience altered neuroactive steroid levels associated with persistent depression symptoms even after stopping finasteride treatment.

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

In this study, several compounds, including estrogen and Dutasteride, showed neuroprotective effects on dopaminergic neurons in an MPTP mouse model of Parkinson's disease.

This study suggests that synthetic steroid analogues or 5α-reductase modulation could be potential therapeutic strategies for nervous system disorders, but further research on their effects is necessary.

This review examines the methods and challenges in androgen laboratory diagnostics, discussing their advantages, limitations, and evolution; it presents no new experimental results.

This study discusses the complex roles and effects of brain-synthesized sex neurosteroids, highlighting sex differences in their concentrations and their varied impacts on synaptic plasticity, cognitive behavior, and aging-related cognitive decline.

This review discusses the role of neurosteroids and androgens throughout different life stages, noting the potential disruptions caused by 5α-reductase inhibitors like finasteride, but no new clinical results are reported.

This review discusses recent strategies targeting the neuroactive steroid biosynthetic pathway to enhance neurosteroidogenesis, highlighting their potential benefits for neurodegenerative and neuropsychiatric diseases, but reports no new clinical findings.

This review proposes focusing on relationships between neuroactive steroids and psychiatric disorder symptoms, rather than relying on traditional disorder classifications, and reports no new clinical findings.

This study observed that androgenic alopecia patients taking finasteride had altered neuroactive steroid levels and persistent depression symptoms even after stopping the treatment.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

This study found that men experiencing long-term symptoms after finasteride use for androgenetic alopecia frequently reported loss of penis sensitivity and anhedonia, among other effects, indicating potential post-finasteride syndrome.

This review discusses the current understanding of androgen biosynthesis, mechanisms of action, and their roles in human biology, as well as related congenital and acquired disorders, but it reports no new research findings.

This review discusses androgenetic alopecia management with 5α-reductase inhibitors, emphasizing that while dutasteride shows superior efficacy, finasteride is suggested as preferable due to predictable adverse effects and preservation of physiological roles.

This discussion highlights the use of minimal incision extraction for lipoma removal, noting that it is a favored technique among dermatologists due to its efficiency, despite some hesitance with larger lipomas.

This review analyzes how androgens impact sexual desire and reproductive behaviors, emphasizing molecular interactions, but provides no new clinical results.

This study found that finasteride treatment in males with androgenetic alopecia was linked to significant changes in sperm parameters and increased testosterone levels, but no sexual dysfunction was observed, and sperm parameters returned to baseline after treatment stopped.

This review discusses sex differences in Parkinson's disease and highlights that while men are more frequently affected, androgen-modulating treatments have not yet proven effective for PD, though 5α-reductase inhibitors show potential for further study.